Effect of Canagliflozin (CANA) on Liver Function Tests (LFTs) in Patients with Type 2 Diabetes Mellitus (T2DM)

被引：0
|
作者：
Usiskin, Keith
Leiter, Lawrence A.
Forst, Thomas
Polidori, David
Xie, John
Sha, Sue
机构：
来源：
DIABETES | 2014年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1092-P
引用
收藏
页码：A284 / A284
页数：1
相关论文
共 50 条
  • [31] THE COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS SAXAGLIPTIN (SAXA) AMONG OLDER INDIVIDUALS LIVING WITH TYPE 2 DIABETES MELLITUS (T2DM) IN CANADA
    Teschemaker, A. R.
    Neslusan, C.
    Sabapathy, S.
    Yoong, K.
    Johansen, P.
    Willis, M.
    [J]. VALUE IN HEALTH, 2015, 18 (03) : A62 - A63
  • [32] The cost-effectiveness of canagliflozin (CANA) versus sitagliptin (SITA) as third-line therapy in the treatment of type 2 diabetes mellitus (T2DM) in the UK
    Thompson, G.
    Schroeder, M.
    Neslusan, C.
    Willis, M.
    Johansen, P.
    Teschemaker, A.
    [J]. DIABETOLOGIA, 2014, 57 : S330 - S330
  • [33] THE COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS DAPAGLIFLOZIN (DAPA) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) WITH INADEQUATE CONTROL ON METFORMIN (MET) MONOTHERAPY IN THE UNITED KINGDOM
    Schroeder, M.
    Johansen, P.
    Thompson, G.
    Willis, M.
    Neslusan, C.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A344 - A344
  • [34] COST-EFFECTIVENESS ANALYSIS OF CANAGLIFLOZIN (CANA) VERSUS DAPAGLIFLOZIN (DAPA) AS AN ADD-ON TO METFORMIN (MET) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN THE UNITED STATES
    Neslusan, C.
    Teschemaker, A.
    Martin, S.
    Willis, M.
    Johansen, P.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A248 - A248
  • [35] The Cost-Effectiveness of Canagliflozin (CANA) vs. Sitagliptin as an Add-on to Metformin (MET) in the Treatment of Type 2 Diabetes Mellitus (T2DM) in the US
    Martin, Silas
    Neslusan, Cheryl
    Vo, Lien
    Teschemaker, Anna
    Johansen, Pierre
    Willis, Michael
    [J]. DIABETES, 2014, 63 : A310 - A310
  • [36] Pharmacogenomics and pharmacomicrobiomics in type 2 diabetes mellitus (T2DM)
    Luo, Jian-Quan
    Shu, Yan
    Zhang, Wei
    [J]. FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [37] Vascular responsiveness in type 2 diabetes mellitus (T2DM)
    Blum, A.
    Socea, D.
    Sirchan, R.
    [J]. QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2016, 109 (12) : 791 - 796
  • [38] The platelets characteristics in type 2 diabetes mellitus (T2DM)
    Buryachkovskaya, L.
    Uchitel, I. A.
    Sumarokov, A. B.
    Docenko, U., V
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 931 - 931
  • [39] Microvascular complications in type 2 diabetes mellitus (T2DM).
    Cheung, AT
    Ramanujam, S
    Duong, PL
    Schauer, D
    Chan, LS
    Dwyre, DM
    Larkin, EC
    [J]. FASEB JOURNAL, 2002, 16 (04): : A208 - A208
  • [40] Target Achievement and Quality Measure (QM) Attainment with Titrated Canagliflozin (CANA) in Patients with Type 2 Diabetes Mellitus (T2DM) as Add-on to Metformin (MET) plus Sitagliptin (SITA)
    Seufert, Jochen
    Aggarwal, Naresh
    Bailey, Robert
    Cao, Anjun
    Fung, Albert
    Pfeifer, Michael
    Alba, Maria
    Rodbard, Helena W.
    [J]. DIABETES, 2016, 65 : A308 - A308
12345